Health Care·Health Care Supplies·$11.9B
Solventum Corp operates in the health care sector, focusing on health care supplies. With a market cap of $12 billion, the company plays a crucial role in providing essential medical products, which are increasingly important as global health care demands rise.
Earnings Per Share (EPS)
EPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.
Revenue Growth
Revenue growth will indicate how well Solventum is expanding its market share and meeting customer demand in the health care supplies sector.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+12.17%
Avg Stock Reaction
+0.54%
In Q4 2025, Solventum reported an EPS of $1.57, beating estimates by 4.67%. The stock reacted positively, gaining 2.48% the following day.
Management Promises & Guidance
Investors are generally optimistic about Solventum's upcoming earnings, given its strong track record of beating EPS estimates. However, there is uncertainty due to the lack of specific revenue guidance.
Bull Case
If Solventum continues its trend of beating EPS estimates, it could signal strong operational performance and market demand, leading to a positive stock reaction.
Bear Case
Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, especially given the high implied volatility.
Earnings Per Share (EPS)
N/AEPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.
Revenue Growth
N/ARevenue growth will indicate how well Solventum is expanding its market share and meeting customer demand in the health care supplies sector.
The print will turn on these two things.
Q1
What is the expected EPS for Q1-2026?
The EPS figure will be crucial in assessing the company's profitability and operational efficiency, impacting investor sentiment.
Q2
How is revenue growth trending compared to previous quarters?
Understanding revenue trends will provide insight into market demand and the company's ability to capture growth in the health care supplies sector.
Why consensus could be wrong
The market may be underestimating Solventum's ability to innovate and capture market share in a growing health care sector, despite the lack of guidance.
Supporting Evidence
The company has consistently beaten EPS estimates, indicating strong management performance.
Options pricing suggests a larger move than historical averages, indicating heightened expectations.
The health care supplies market is expected to grow, providing a favorable backdrop for Solventum.
Key Risk
If the company reports an EPS significantly above $1.60, it could shift market sentiment positively.
Pre-commit to what would confirm each case.
The core debate centers around whether Solventum can sustain its growth trajectory and profitability in a competitive health care market.
Bull Confirmed If
An EPS of $1.60 or higher would confirm strong operational performance and positive market sentiment.
Bear Confirmed If
An EPS below $1.40 would raise concerns about profitability and market demand.
Implied Move
±7.57%
Historical Avg
±2.1%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±7.6% while SOLV has averaged ±2.1% over the last 8 prints — setup is pricing rich.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Solventum beats expectations, history suggests the stock could rise by about 0.54% on the first day, confirming strong demand and operational efficiency.
In-Line / Cautious
If results are in line with expectations but management provides cautious commentary, the stock may experience a muted reaction as investors weigh future growth prospects.
Miss
Should the company miss expectations, history suggests a potential decline of around 2.08%, reflecting investor disappointment and concerns about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026